



Mirum Pharmaceuticals to Participate in September Investor Conferences

September 2, 2021

FOSTER CITY, Calif.--(BUSINESS WIRE)--Sep. 2, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will participate in five investor conferences taking place virtually throughout the month of September.

Citi 16th Annual BioPharma Virtual Conference

September 10, 2021

Format: One-on-one meetings

H.C. Wainwright 23rd Annual Global Investor Conference

September 13-14, 2021

Format: [Company presentation](#) (available September 13 at 7:00 a.m. ET) and one-on-one meetings.

Baird Global Healthcare Conference

September 14-15, 2021

Format: Company presentation (September 14 at 12:50 p.m. ET) and one-on-one meetings.

Leerink CyberRX Series 1x1 Event

September 22-23, 2021

Format: One-on-one meetings.

Cantor Global Healthcare Conference

September 27-29, 2021

Format: [Company presentation](#) (September 27 at 2:40 p.m. ET) and one-on-one meetings.

Visit the [Investors and Media](#) section of Mirum's corporate website for additional information.

About Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Mirum's lead product candidate, maralixibat, is an investigational oral drug in development for Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), and biliary atresia. Mirum has submitted an NDA for maralixibat in the treatment of cholestatic pruritus in patients with ALGS. The NDA has been accepted for priority review by the FDA with a PDUFA action date of September 29, 2021. Additionally, Mirum's marketing authorization application for the treatment of pediatric patients with PFIC2 has been accepted for review (validated) by the European Medicines Agency. Mirum is also developing volixibat, also an oral ASBT-inhibitor, in primary sclerosing cholangitis, intrahepatic cholestasis of pregnancy, and primary biliary cholangitis. For more information, visit MirumPharma.com.

To augment its pipeline in cholestatic liver disease, Mirum has acquired the exclusive option to develop and commercialize gene therapy programs VTX-803 and VTX-802 for PFIC3 and PFIC2, respectively, from Vivet Therapeutics SAS, following preclinical evaluation and investigational new drug-enabling studies.

Follow Mirum on [Twitter](#), [Facebook](#), [LinkedIn](#) and [Instagram](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210902005855/en/): <https://www.businesswire.com/news/home/20210902005855/en/>

Media:

Erin Murphy

media@mirumpharma.com

Investors:

Ian Clements, Ph.D.

ir@mirumpharma.com

Sam Martin

Argot Partners

ir@mirumpharma.com

Source: Mirum Pharmaceuticals, Inc.